加齢性黄斑変性症（ARMD）薬の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Age-relatedMacularDegeneration (ARMD) Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-14666 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、107ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、加齢性黄斑変性症（ARMD）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。加齢性黄斑変性症（ARMD）薬の種類別市場規模（抗VEGF薬、光感受性薬、その他）、用途別市場規模（滲出型ARMD、萎縮型ARMD）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、TRACON Pharmaceuticals、Santen Oy、Regeneron Pharmaceuticals、Eli Lilly and Company、Bayer、GSK、Novartis、Kanghong Pharmaceuticals、Pfizer、BIOCAD ・地域別グローバル市場分析 2015年-2020年 ・加齢性黄斑変性症（ARMD）薬の北米市場（アメリカ、カナダ、メキシコ） ・加齢性黄斑変性症（ARMD）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・加齢性黄斑変性症（ARMD）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・加齢性黄斑変性症（ARMD）薬の南米市場（ブラジル、アルゼンチン） ・加齢性黄斑変性症（ARMD）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：抗VEGF薬、光感受性薬、その他 ・用途別分析：滲出型ARMD、萎縮型ARMD ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The Age-relatedMacularDegeneration (ARMD) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Age-relatedMacularDegeneration (ARMD) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Market segmentation
Age-relatedMacularDegeneration (ARMD) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Age-relatedMacularDegeneration (ARMD) Drugs market has been segmented into:
Anti VEGF Drugs
Photosensitive Drugs
Others

By Application, Age-relatedMacularDegeneration (ARMD) Drugs has been segmented into:
Exudative ARMD
Atrophy ARMD

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Age-relatedMacularDegeneration (ARMD) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Age-relatedMacularDegeneration (ARMD) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Age-relatedMacularDegeneration (ARMD) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Age-relatedMacularDegeneration (ARMD) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Age-relatedMacularDegeneration (ARMD) Drugs Market Share Analysis
Age-relatedMacularDegeneration (ARMD) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Age-relatedMacularDegeneration (ARMD) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Age-relatedMacularDegeneration (ARMD) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Age-relatedMacularDegeneration (ARMD) Drugs are:
Roche
TRACON Pharmaceuticals
Santen Oy
Regeneron Pharmaceuticals
Eli Lilly and Company
Bayer
GSK
Novartis
Kanghong Pharmaceuticals
Pfizer
BIOCAD
Among other players domestic and global, Age-relatedMacularDegeneration (ARMD) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

レポート目次

---

1 Age-relatedMacularDegeneration (ARMD) Drugs Market Overview
1.1 Product Overview and Scope of Age-relatedMacularDegeneration (ARMD) Drugs
1.2 Classification of Age-relatedMacularDegeneration (ARMD) Drugs by Type
1.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type in 2019
1.2.3 Anti VEGF Drugs
1.2.4 Photosensitive Drugs
1.2.5 Others
1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Application
1.3.1 Overview: Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Exudative ARMD
1.3.3 Atrophy ARMD
1.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Market by Regions
1.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Age-relatedMacularDegeneration (ARMD) Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Age-relatedMacularDegeneration (ARMD) Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Age-relatedMacularDegeneration (ARMD) Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Age-relatedMacularDegeneration (ARMD) Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Age-relatedMacularDegeneration (ARMD) Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Age-relatedMacularDegeneration (ARMD) Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 TRACON Pharmaceuticals
2.2.1 TRACON Pharmaceuticals Details
2.2.2 TRACON Pharmaceuticals Major Business
2.2.3 TRACON Pharmaceuticals SWOT Analysis
2.2.4 TRACON Pharmaceuticals Product and Services
2.2.5 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Santen Oy
2.3.1 Santen Oy Details
2.3.2 Santen Oy Major Business
2.3.3 Santen Oy SWOT Analysis
2.3.4 Santen Oy Product and Services
2.3.5 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Regeneron Pharmaceuticals
2.4.1 Regeneron Pharmaceuticals Details
2.4.2 Regeneron Pharmaceuticals Major Business
2.4.3 Regeneron Pharmaceuticals SWOT Analysis
2.4.4 Regeneron Pharmaceuticals Product and Services
2.4.5 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company SWOT Analysis
2.5.4 Eli Lilly and Company Product and Services
2.5.5 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bayer
2.6.1 Bayer Details
2.6.2 Bayer Major Business
2.6.3 Bayer Product and Services
2.6.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 GSK
2.7.1 GSK Details
2.7.2 GSK Major Business
2.7.3 GSK Product and Services
2.7.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Product and Services
2.8.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Kanghong Pharmaceuticals
2.9.1 Kanghong Pharmaceuticals Details
2.9.2 Kanghong Pharmaceuticals Major Business
2.9.3 Kanghong Pharmaceuticals Product and Services
2.9.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Product and Services
2.10.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 BIOCAD
2.11.1 BIOCAD Details
2.11.2 BIOCAD Major Business
2.11.3 BIOCAD Product and Services
2.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share
3.2.2 Top 10 Age-relatedMacularDegeneration (ARMD) Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Market Share by Regions
4.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
5 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries
5.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
5.2 USA Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
6 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries
6.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
6.2 Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
6.4 France Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries
7.1 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
7.2 China Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
7.5 India Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
8 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries
8.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
8.2 Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Age-relatedMacularDegeneration (ARMD) Drugs by Countries
9.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Type (2019-2024)
10.3 Anti VEGF Drugs Revenue Growth Rate (2015-2025)
10.4 Photosensitive Drugs Revenue Growth Rate (2015-2025)
10.5 Others Revenue Growth Rate (2015-2025)
11 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Segment by Application
11.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application (2015-2020)
11.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Application (2019-2024)
11.3 Exudative ARMD Revenue Growth (2015-2020)
11.4 Atrophy ARMD Revenue Growth (2015-2020)
12 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast (2021-2025)
12.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast (2021-2025)
12.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Forecast by Regions (2021-2025)
12.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
12.6 South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Age-relatedMacularDegeneration (ARMD) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 8. Roche Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 11. Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. TRACON Pharmaceuticals Corporate Information, Location and Competitors
Table 13. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 14. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2018-2019)
Table 15. TRACON Pharmaceuticals SWOT Analysis
Table 16. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 17. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Santen Oy Corporate Information, Location and Competitors
Table 19. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 20. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 21. Santen Oy SWOT Analysis
Table 22. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 23. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Regeneron Pharmaceuticals Corporate Information, Location and Competitors
Table 25. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 26. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 27. Regeneron Pharmaceuticals SWOT Analysis
Table 28. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 29. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Eli Lilly and Company Corporate Information, Location and Competitors
Table 31. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 32. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 33. Eli Lilly and Company SWOT Analysis
Table 34. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 35. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Bayer Corporate Information, Location and Competitors
Table 37. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 38. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 39. Bayer SWOT Analysis
Table 40. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 41. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. GSK Corporate Information, Location and Competitors
Table 43. GSK Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 44. GSK Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 45. GSK SWOT Analysis
Table 46. GSK Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 47. GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Novartis Corporate Information, Location and Competitors
Table 49. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 50. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 51. Novartis SWOT Analysis
Table 52. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 53. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Kanghong Pharmaceuticals Corporate Information, Location and Competitors
Table 55. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 56. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 57. Kanghong Pharmaceuticals SWOT Analysis
Table 58. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 59. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Pfizer Corporate Information, Location and Competitors
Table 61. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 62. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 63. Pfizer SWOT Analysis
Table 64. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 65. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. BIOCAD Corporate Information, Location and Competitors
Table 67. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Major Business
Table 68. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Total Revenue (USD Million) (2017-2018)
Table 69. BIOCAD SWOT Analysis
Table 70. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Product and Solutions
Table 71. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Players (2015-2020)
Table 73. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players (2015-2020)
Table 74. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Regions (2015-2020)
Table 75. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Regions (2015-2020)
Table 76. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
Table 77. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Table 78. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 79. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 80. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Countries (2015-2020)
Table 81. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Table 82. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 83. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Table 84. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) by Type (2015-2020)
Table 85. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Type (2015-2020)
Table 86. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Forecast by Type (2021-2025)
Table 87. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Application (2015-2020)
Table 88. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2015-2020)
Table 89. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Forecast by Application (2021-2025)
Table 90. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Picture
Figure 2. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type in 2019
Figure 3. Anti VEGF Drugs Picture
Figure 4. Photosensitive Drugs Picture
Figure 5. Others Picture
Figure 6. Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Application in 2019
Figure 7. Exudative ARMD Picture
Figure 8. Atrophy ARMD Picture
Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share in 2019
Figure 18. Global Top 10 Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Regions (2015-2020)
Figure 22. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Regions in 2018
Figure 23. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 24. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 26. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 28. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Figure 29. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries in 2019
Figure 30. USA Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 31. Canada Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 33. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries in 2019
Figure 35. Germany Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 36. UK Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 37. France Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Russia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 39. Italy Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries in 2019
Figure 42. China Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Japan Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Korea Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 45. India Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 47. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Figure 48. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries in 2019
Figure 49. Brazil Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 54. UAE Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue and Growth Rate (2015-2020)
Figure 57. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Type (2015-2020)
Figure 58. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Type in 2019
Figure 59. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Type (2021-2025)
Figure 60. Global Anti VEGF Drugs Revenue Growth Rate (2015-2020)
Figure 61. Global Photosensitive Drugs Revenue Growth Rate (2015-2020)
Figure 62. Global Others Revenue Growth Rate (2015-2020)
Figure 63. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application (2015-2020)
Figure 64. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Share by Application in 2019
Figure 65. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share Forecast by Application (2021-2025)
Figure 66. Global Exudative ARMD Revenue Growth Rate (2015-2020)
Figure 67. Global Atrophy ARMD Revenue Growth Rate (2015-2020)
Figure 68. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
Figure 72. Europe Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
Figure 74. South America Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel

---